UAE
Bahrain
Jordan
Kuwait
Oman
Qatar
Saudi ArabiaHealth News
SMi's Annual Pre-Filled Syringes, 27th-28th January 2014, Marriott Regents Park Hotel, London
Date: Sep-09-2013Pre-Filled Syringes in Europe SMi Group reports: 2 days,18 unique presentations, 20 speakers. Registration for the 6th Annual Pre-Filled Syringes is now open.SMi Group reports: Registration for Annual Pre-Filled Syringes - 2014 is now open. With one of the most established European market leaders on this subject and the huge successes of their previous meetings, SMi will provide another great forum for new advances in this field...
Research yields first detailed view of morphing Parkinson's protein
Date: Sep-09-2013Researchers have taken detailed images and measurements of the morphing structure of a brain protein thought to play a role in Parkinson's disease, information that could aid the development of medications to treat the condition. The protein, called alpha synuclein (pronounced sine-yoo-cline), ordinarily exists in a globular shape. However, the protein morphs into harmful structures known as amyloid fibrils, which are linked to protein molecules that form in the brains of patients with neurodegenerative diseases...
AesRx anti-sickling drug AES-103 begins Phase 2 trial
Date: Sep-09-2013AesRx, LLC, announced it has received regulatory and ethics committee approval for a Phase 2 clinical trial of its novel Aes-103 anti-sickling agent in patients with sickle cell disease (SCD). The Company plans for patient enrollment to start this month. This is the first Phase 2 trial of Aes-103 for SCD and as such marks an important milestone in the drug's development. This double-blind, placebo controlled study will evaluate the safety and pharmacokinetics of 28-day dosing of Aes-103. In addition, the impact of Aes-103 on several sickle cell clinical endpoints will be evaluated...
Brain clues reveal risk of psychotic illness
Date: Sep-09-2013New research has shown that people with psychotic illness show similar brain changes to immediate family members who present no signs of illness. In a study published today in the journal JAMA Psychiatry, researchers at Monash University, in collaboration with The University of Melbourne and the University of Cambridge, UK, found that these brain changes represent a marker of genetic risk of developing psychotic illnesses, such as schizophrenia...
No adverse effects in volunteers following Phase I clinical trial of Sumagen AIDS vaccine
Date: Sep-09-2013Sumagen Canada Inc and Western University has announced that the Phase I Clinical Trial (SAV CT 01) of the first and only preventative HIV vaccine based on a genetically modified killed whole virus (SAV001-H) has been successfully completed with no adverse effects in all patients. Antibody production was also boosted after vaccination. Developed by Dr...
Pivotal study supports use of IMNOVID® - (pomalidomide) in patients with relapsed or refractory multiple myeloma
Date: Sep-09-2013The Lancet Oncology has published findings from a study, which showed that the new oral therapy IMNOVID® - (pomalidomide), used in combination with low-dose dexamethasone demonstrated a significant survival advantage over high-dose dexamethasone alone, in patients with relapsed and refractory multiple myeloma (rrMM).[1] "Unfortunately the prognosis for relapsed and refractory multiple myeloma is poor as there are few effective therapeutic options for people living with this disease" said Professor Steve Schey, Kings College London, author and UK Principal Investigator of the study...
Investigational submicron diclofenac reduces use of opioid rescue medication in post-surgical pain in a Phase 3 study
Date: Sep-09-2013Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, has announced that the company's investigational, non-steroidal anti-inflammatory drug (NSAID) submicron diclofenac reduced the use of opioid rescue medication in patients with acute pain following bunionectomy surgery. Specifically, the study showed that significantly fewer patients who received submicron particle diclofenac capsules 35 mg (82 percent; P = 0.002) or 18 mg (85 percent; P = 0.005), or who received active comparator celecoxib (85 percent; P = 0...
Florida coastal seaweed could help the body fend off cancers and inflammatory diseases
Date: Sep-09-2013A new defense against prostate cancer, the most common cancer in men in the United States, may come from a seaweed found off the coast of Florida. University of Florida pharmacy researchers have screened various seaweeds with cancer-preventive potential and identified one that shows particular promise. They isolated specific compounds in this common green alga, known as sea lettuce, and undertook studies to understand exactly how they work. Their findings, published Sept...
Chemical composition of human urine determined
Date: Sep-09-2013Researchers at the University of Alberta have announced that they have determined the chemical composition of human urine. The study, which took more than seven years and involved a team of nearly 20 researchers, has revealed that more than 3,000 chemicals or "metabolites" can be detected in urine. The results are expected to have significant implications for medical, nutritional, drug and environmental testing. "Urine is an incredibly complex biofluid...
Children with behavioral problems more at risk of inflammation
Date: Sep-09-2013Children with behavioral problems may be at risk of many chronic diseases in adulthood including heart disease, obesity, diabetes, as well as inflammatory illnesses (conditions which are caused by cell damage). Analyzing data on more than 4,000 participants in the Children of the 90s study at the University of Bristol, researchers from Harvard and Columbia's Mailman School of Public Health found that children with behavioral problems at the age of 8, had higher levels of two proteins (C-reactive protein - CRP; and Interleukin 6-IL-6) in their blood when tested at the age of 10...
Stay Connected
